Lipocine Inc. Files 8-K: Other Events & Financials

Ticker: LPCN · Form: 8-K · Filed: 2024-12-17T00:00:00.000Z

Sentiment: neutral

Topics: sec-filing, 8-k, financials

TL;DR

Lipocine filed an 8-K today for other events and financials.

AI Summary

Lipocine Inc. filed an 8-K on December 17, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not detail specific transactions or financial results but serves as a notification of these items being filed.

Why It Matters

This 8-K filing indicates that Lipocine Inc. has submitted important updates regarding its business operations and financial status to the SEC.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of events and financial statements without immediate material impact disclosed.

Key Players & Entities

FAQ

What specific 'Other Events' are being reported by Lipocine Inc. in this 8-K?

The provided text of the 8-K filing indicates 'Other Events' as an item information, but does not specify the nature of these events.

When was this 8-K filing submitted to the SEC?

The filing was submitted on December 17, 2024.

What is the Commission File Number for Lipocine Inc.'s 8-K filing?

The Commission File Number is 001-36357.

Where is Lipocine Inc. headquartered?

Lipocine Inc.'s principal executive offices are located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.

Does this filing provide details on Lipocine Inc.'s financial performance?

The filing lists 'Financial Statements and Exhibits' as an item information, suggesting financial information is included, but the specific details are not provided in the excerpt.

From the Filing

0001493152-24-050346.txt : 20241217 0001493152-24-050346.hdr.sgml : 20241217 20241217093010 ACCESSION NUMBER: 0001493152-24-050346 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20241217 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241217 DATE AS OF CHANGE: 20241217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lipocine Inc. CENTRAL INDEX KEY: 0001535955 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 990370688 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36357 FILM NUMBER: 241553829 BUSINESS ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 BUSINESS PHONE: 801 994 7383 MAIL ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 FORMER COMPANY: FORMER CONFORMED NAME: MARATHON BAR CORP DATE OF NAME CHANGE: 20111130 8-K 1 form8-k.htm false 0001535955 0001535955 2024-12-17 2024-12-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of Earliest Event Reported): December 17, 2024     LIPOCINE INC. (Exact name of registrant as specified in its charter)   Commission File No. 001-36357   Delaware   99-0370688 (State or other jurisdiction of incorporation)   (IRS Employer Identification Number)   675 Arapeen Drive , Suite 202 Salt Lake City , Utah 84108 (Address of principal executive offices) (Zip Code)   Registrant’s telephone number, including area code: (801) 994-7383   Former name or former address, if changed since last report: Not Applicable       Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   LPCN   The NASDAQ Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 8.01 Other Events   The Company issued a press release announcing that the FDA has granted Fast Track Designation to LPCN 1148, as a treatment for sarcopenia in patients with decompensated cirrhosis. The press release is filed as Exhibits 99.1.   Item 9.01 Financial Statements and Exhibits.   (d) Exhibits   The following exhibits are filed with this report:   Exhibit No.   Description 99.1   Press Release announcing FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for

View on Read The Filing